Geographical variation in Plasmodium vivax relapse

[1]  Leah Blau,et al.  Statistical Models In Epidemiology , 2016 .

[2]  David L. Smith,et al.  Geographical variation in Plasmodium vivax relapse , 2014, Malaria Journal.

[3]  S. Krudsood,et al.  Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study , 2014, The Lancet.

[4]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[5]  N. White,et al.  The activation of vivax malaria hypnozoites by infectious diseases. , 2013, The Lancet. Infectious diseases.

[6]  R. Coker,et al.  Quantifying Effect of Geographic Location on Epidemiology of Plasmodium vivax Malaria , 2013, Emerging infectious diseases.

[7]  Mulyanto,et al.  The Evolutionary History of Plasmodium vivax as Inferred from Mitochondrial Genomes: Parasite Genetic Diversity in the Americas , 2013, Molecular biology and evolution.

[8]  Susanne A. Fritz,et al.  An Update of Wallace’s Zoogeographic Regions of the World , 2013, Science.

[9]  M. Galinski,et al.  Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targets. , 2013, Advances in parasitology.

[10]  S. Hay,et al.  G6PD deficiency: global distribution, genetic variants and primaquine therapy. , 2013, Advances in parasitology.

[11]  X. Su,et al.  Molecular and epidemiological characterization of Plasmodium vivax recurrent infections in southern Mexico , 2013, Parasites & Vectors.

[12]  J. Burrows,et al.  The global pipeline of new medicines for the control and elimination of malaria , 2012, Malaria Journal.

[13]  David L. Smith,et al.  A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010 , 2012, PLoS neglected tropical diseases.

[14]  P. Gething,et al.  The global public health significance of Plasmodium vivax. , 2012, Advances in parasitology.

[15]  N. White.  Determinants of relapse periodicity in Plasmodium vivax malaria , 2011, Malaria Journal.

[16]  David L. Smith,et al.  Modelling the global constraints of temperature on transmission of Plasmodium falciparum and P. vivax , 2011, Parasites & Vectors.

[17]  Caroline W. Kabaria,et al.  The dominant Anopheles vectors of human malaria in the Asia-Pacific region: occurrence data, distribution maps and bionomic précis , 2011, Parasites & Vectors.

[18]  Teun Bousema,et al.  Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and Elimination , 2011, Clinical Microbiology Reviews.

[19]  R. Price,et al.  Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  David L. Smith,et al.  Erratum: Ranking of elimination feasibility between malaria-endemic countries (Lancet (2010) 376 (1579-1591)) , 2011 .

[21]  J. Baird.  Eliminating malaria—all of them , 2010, The Lancet.

[22]  Andrew J Tatem,et al.  Ranking of elimination feasibility between malaria-endemic countries , 2010, The Lancet.

[23]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[24]  R. Price,et al.  Artemisinin combination therapy for vivax malaria. , 2010, The Lancet. Infectious diseases.

[25]  Anand P. Patil,et al.  Estimating the Global Clinical Burden of Plasmodium falciparum Malaria in 2007 , 2010, PLoS medicine.

[26]  Sue J Lee,et al.  Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial , 2010, Malaria Journal.

[27]  J. Baird,et al.  Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. , 2010, Trends in parasitology.

[28]  L. Hedges,et al.  The Handbook of Research Synthesis and Meta-Analysis , 2009 .

[29]  R. Price,et al.  New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance , 2009, Current opinion in infectious diseases.

[30]  J. Baird,et al.  Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. , 2009, The Lancet. Infectious diseases.

[31]  Simon I Hay,et al.  Defining the relationship between Plasmodium falciparum parasite rate and clinical disease: statistical models for disease burden estimation , 2009, Malaria Journal.

[32]  R. Price,et al.  Vivax malaria: a major cause of morbidity in early infancy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Bruce Russell,et al.  The pathophysiology of vivax malaria. , 2009, Trends in parasitology.

[34]  Stephen W. Raudenbush,et al.  Analyzing effect sizes: Random-effects models. , 2009 .

[35]  R. Price,et al.  Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum , 2008, Malaria Journal.

[36]  R. Price,et al.  Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia , 2008, PLoS medicine.

[37]  M. Alpers,et al.  Plasmodium vivax and Mixed Infections Are Associated with Severe Malaria in Children: A Prospective Cohort Study from Papua New Guinea , 2008, PLoS medicine.

[38]  R. Price,et al.  Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  Nicholas J White,et al.  Vivax malaria: neglected and not benign. , 2007, The American journal of tropical medicine and hygiene.

[40]  I. Elyazar,et al.  Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. , 2007, The American journal of tropical medicine and hygiene.

[41]  T. McMahon,et al.  Updated world map of the Köppen-Geiger climate classification , 2007 .

[42]  R. Price,et al.  Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison , 2007, The Lancet.

[43]  A. Omari,et al.  Primaquine for preventing relapses in people with Plasmodium vivax malaria. , 2007, The Cochrane database of systematic reviews.

[44]  Andrew J Tatem,et al.  Assembling a global database of malaria parasite prevalence for the Malaria Atlas Project , 2007, Malaria Journal.

[45]  J. Carmona-Fonseca,et al.  Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. , 2006, The American journal of tropical medicine and hygiene.

[46]  H. Dagoro,et al.  Are insecticide-treated bednets more protective against Plasmodium falciparum than Plasmodium vivax-infected mosquitoes? , 2006, Malaria Journal.

[47]  Wolfgang Viechtbauer,et al.  Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model , 2005 .

[48]  A. Das,et al.  Plasmodium vivax Malaria , 2005, Emerging infectious diseases.

[49]  S. Hoffman,et al.  Primaquine therapy for malaria. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  J. Baird,et al.  Chloroquine Resistance in Plasmodium vivax , 2004, Antimicrobial Agents and Chemotherapy.

[51]  J. Sattabongkot,et al.  Plasmodium vivax transmission: chances for control? , 2004, Trends in parasitology.

[52]  J. Baird,et al.  Can primaquine therapy for vivax malaria be improved? , 2003, Trends in parasitology.

[53]  F. McKenzie,et al.  PLASMODIUM VIVAX BLOOD-STAGE DYNAMICS , 2002, The Journal of parasitology.

[54]  J. Sullivan,et al.  EXPERIMENTAL INFECTION OF ANOPHELES FARAUTI WITH DIFFERENT SPECIES OF PLASMODIUM , 2002, The Journal of parasitology.

[55]  J. Sachs,et al.  The economic and social burden of malaria , 2002, Nature.

[56]  G. Powell,et al.  Terrestrial Ecoregions of the World: A New Map of Life on Earth , 2001 .

[57]  K. Mendis,et al.  The neglected burden of Plasmodium vivax malaria. , 2001, The American journal of tropical medicine and hygiene.

[58]  N. Gogtay,et al.  Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections. , 1999, Annals of tropical medicine and parasitology.

[59]  S. Lal,et al.  Epidemiology and control of malaria , 1999, Indian journal of pediatrics.

[60]  W. Perea,et al.  Permethrin-impregnated bed nets for the prevention of malaria in schoolchildren on the Thai-Burmese border. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[61]  Pandey Kc,et al.  Role of An. culicifacies and An. stephensi in malaria transmission in urban Delhi. , 1993 .

[62]  S. Subbarao,et al.  Role of An. culicifacies and An. stephensi in malaria transmission in urban Delhi. , 1993, Indian journal of malariology.

[63]  K Ulm,et al.  A simple method to calculate the confidence interval of a standardized mortality ratio (SMR) , 1990, American journal of epidemiology.

[64]  K. Rieckmann,et al.  PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE? , 1989, The Lancet.

[65]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[66]  W. Wernsdorfer,et al.  Malaria: Principles and Practice of Malariology , 1989 .

[67]  Krotoski Wa,et al.  The hypnozoite and malarial relapse. , 1989 .

[68]  W A Krotoski,et al.  The hypnozoite and malarial relapse. , 1989, Progress in clinical parasitology.

[69]  W. Wernsdorfer,et al.  Malaria parasites of man: life-cycles and morphology (excluding ultrastructure). , 1988 .

[70]  S. Looareesuwan,et al.  HIGH RATE OF PLASMODIUM VIVAX RELAPSE FOLLOWING TREATMENT OF FALCIPARUM MALARIA IN THAILAND , 1987, The Lancet.

[71]  G. R. Coatney.  Relapse in malaria--an enigma. , 1976, Journal of Parasitology.

[72]  P. G. Shute,et al.  A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. , 1976, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[73]  P. G. Shute,et al.  A strain of Plasmodium vivax characterized by prolonged incubation: morphological and biological characteristics. , 1975, Bulletin of the World Health Organization.

[74]  W. Collins,et al.  Primate malarias. , 1974, Advances in veterinary science and comparative medicine.

[75]  A. Gehani,et al.  [G6PD deficiency]. , 1974, Xianggang hu li za zhi. The Hong Kong nursing journal.

[76]  H. Notopuro,et al.  Glucose-6-phosphate dehydrogenase deficiency. , 1972, Paediatrica Indonesiana.

[77]  Rakitzis Et,et al.  ENZYME-STRIP ESTIMATION OF BLOOD-GLUCOSE. , 1964 .

[78]  D. Mattingly,et al.  INTRACRANIAL HYPERTENSION AND STEROIDS. , 1964, Lancet.

[79]  J. Beck.  A Textbook of Malaria Eradication , 1963 .

[80]  C. Winckel.  Long latency in Plasmodium vivax infections in a temperate zone. , 1955, Documenta de medicina geographica et tropica.

[81]  R. J. Dern,et al.  Natural history of Korean vivax malaria after deliberate inoculation of human volunteers. , 1954, Journal of Laboratory and Clinical Medicine.

[82]  G. Coatney,et al.  Korean vivax malaria. I. Natural history and response to chloroquine. , 1953, The American journal of tropical medicine and hygiene.

[83]  A. Di Lorenzo,et al.  Korean vivax malaria. V. Cure of the infection by primaquine administered during long-term latency. , 1953, The American journal of tropical medicine and hygiene.

[84]  G. Coatney,et al.  Studies in human malaria. XXXI. Comparison of primaquine, isopentaquine, SN-3883, and pamaquine as curative agents against Chesson strain vivax malaria. , 1953, The American journal of tropical medicine and hygiene.

[85]  J. Tukey,et al.  Transformations Related to the Angular and the Square Root , 1950 .

[86]  R. W. Burgess,et al.  STUDIES IN HUMAN MALARIAXVIII. THE LIFE PATTERN OF SPOROZOITE-INDUCED ST. ELIZABETH STRAIN VIVAX MALARIA , 1950 .

[87]  W. C. Cooper,et al.  Studies in human malaria; the protective and therapeutic action of quinacrine against St. Elizabeth strain vivax malaria. , 1949, American journal of hygiene.

[88]  R. Berliner,et al.  STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. V. THE ANTIMALARIAL ACTIVITY OF QUINACRINE. , 1948, Journal of Clinical Investigation.

[89]  Coatney Gr,et al.  Recrudescence and relapse in vivax malaria. , 1948 .

[90]  D. Earle,et al.  Studies on the chemotherapy of the human malarias; the antimalarial activity of quinacrine. , 1948, Journal of Clinical Investigation.

[91]  G. Coatney,et al.  Recrudescence and relapse in vivax malaria. , 1948, Abstracts. International Congress on Tropical Medicine and Malaria.

[92]  M. D. Young,et al.  Studies in Human Malaria. I. The Protective Action of Sulfadiazine and Sulfapyrazine against Sporozoite-induced Falciparum Malaria. , 1949 .

[93]  M. L. Crossley,et al.  RECENT ADVANCES IN CHEMOTHERAPY , 1940, Science.

[94]  M. Boyd.  The Influence of Sporozoite Dosage in Vivax Malaria. , 1940 .

[95]  S. Kitchen,et al.  On the Infectiousness of Patients infected with Plasmodium vivax and Plasmodium falciparum. , 1937 .

[96]  Amico Bigxami.  Concerning the Pathogenesis of Relapses in Malarial Fevers. , 2022 .